AMG-193
- Generic Name
- AMG-193
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT06593522
- Locations
- 🇦🇺
Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia
🇧🇷Instituto do Cancer Estado SP Icesp, Sao Paulo, São Paulo, Brazil
🇺🇸City of Hope National Medical Center, Duarte, California, United States
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion
- Conditions
- Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 188
- Registration Number
- NCT06360354
- Locations
- 🇩🇪
Universitaetsklinikum Heidelberg, Heidelberg, Germany
🇩🇪Universitaetsklinikum Wuerzburg, Wuerzburg, Germany
🇬🇷Alexandra Hospital, Athens, Greece
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
- Conditions
- Thoracic TumorsNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 500
- Registration Number
- NCT06333951
- Locations
- 🇧🇪
Centre Hospitalier Universitaire de Liege - Sart Tilman, Liege, Belgium
🇫🇷Hopital de la Timone, Marseille, France
🇫🇷Institut de Cancerologie de l Ouest Rene Gauducheau, Saint Herblain, France
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
- Conditions
- MTAP-null Non-Small-Cell Lung CancerMTAP-null Solid Tumors
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 53
- Registration Number
- NCT05975073
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇪🇸Hospital Universitari Vall d Hebron, Barcelona, Cataluña, Spain
A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
- Conditions
- Advanced MTAP-null Solid Tumors
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 649
- Registration Number
- NCT05094336
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸California Research Institute, Glendale, California, United States
🇺🇸Fomat Medical Research, Oxnard, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.